How many PD-1 and PD-L1 checkpoint inhibitors do we need?
STUTTGART, Germany I June 19, 2018 I La Merie Publishing released the results of an independent search for and evaluation of PD-1 and PD-L1 immune checkpoint inhibitors in preclinical and clinical development by pharmaceutical companies.
While it may take time, it's an amazing alternative to the expensive, and harmful, retinoids popular with acne sufferers. If you are pregnant, or breast-feeding, or https://restaurantbuitengewoon.com/66659-levitra-kaufen-ohne-rezept-auf-rechnung-65593/ planning to become pregnant while taking this drug, please discuss the risks and benefits. Unfortunately, once you start experiencing these side effects, you have less time to turn to your doctor for help.
If you think you have any kind of condition you may not have it. If you're not sure which one is best for you, you can always look on the internet tadalafil kaufen preis or call a local pharmacy to see what is available and which one works best for your condition. These drugs can be very harmful to children and should only be used when the benefit is considered greater than the risk.
This Competitive Intelligence report analyzes the competitive field of PD-1 and PD-L1 Immune Checkpoint Inhibitors as of June 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage separately for regulated and less regulated markets and differentiates between specific and bi- or multispecific molecules.
Five antibody products targeting the programmed death receptor 1 (PD-1) or the programmed death-ligand 1 (PD-L1) have been approved. Combined sales of the four checkpoint inhibitors marketed in the year 2017 exceeded US$ 10 bln with double and triple digit growth rates, respectively, compared with sales of the previous year. The enormous clinical and commercial success is attracting many biopharmaceutical companies, not only from countries with regulated pharmaceutical markets (USA; Europe, Japan), but also from countries with less regulated markets, especially China.
Analysis of the PD-1 and PD-L1 checkpoint inhibitor pipeline revealed 41 unique molecules in clinical development by pharmaceutical companies, of which 12% are bispecific molecules and 27% are only developed so far in less regulated countries. Further 15 unique molecules are undergoing IND-enabling studies or have already applied for clinical trial of which 40% are bispecific molecules. Most of the molecules are recombinant antibodies or antibody fusion proteins, but some other treatment modalities, such as small molecules, are also appearing in the pipeline.
Projects were identified by search in La Merie’s proprietary R&D drug database as well in national and international clinical trial databases. All findings were verified by company website visits. Additional secondary search tools include, but are not limited to, company press releases, SEC filings, corporate presentations and scientific abstracts.
The report can be obtained at www.pipelinereview.com, La Merie Publishing’s online store:
Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing